The Cancer Research Institute (CRI), Breast Cancer Research Foundation (BRCF), and Parker Institute for Cancer Immunotherapy (PICI) held a join workshop in August 2018 to evaluate the current landscape of immunotherapy in breast cancer research and treatment.
The workshop resulted in the publication in The Lancet Oncology of a perspectives piece, "Immunotherapy and targeted therapy combinations in metastatic breast cancer."
Workshop delegates also proposed a collaborative research project: The Translational Resource for Immuno-Biology to Understand Therapeutic Efficacy (TRIBUTE). TRIBUTE aims to establish a biorepository of tissue and blood samples from breast cancer patients treated with immunotherapy. The biorepository is designed to help researchers better characterize adverse events in a real-world setting, to identify biomarkers of response to therapy as well as of risk for toxicity, and to clarify the impact immunotherapy agents have on the tumor microenvironment.
CRI is proud to co-fund TRIBUTE in partnership with BCRF and PICI. The project is led by Elizabeth Mittendorf, M.D., Ph.D., of Dana-Farber Cancer Institute.